Bill

Bill > S791


NJ S791

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.


summary

Introduced
01/18/2022
In Committee
06/09/2022
Crossed Over
Passed
Dead
01/08/2024

Introduced Session

2022-2023 Regular Session

Bill Summary

This bill requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group health insurers to provide coverage for an annual prostate cancer screening without cost sharing. Under current law, these health insurance carriers are required only to provide coverage for an annual medically recognized diagnostic examination including, but not limited to, a digital rectal examination and a prostate-specific antigen test for men age 50 and over who are asymptomatic and for men age 40 and over with a family history of prostate cancer or other prostate cancer risk factors. The bill expands the definition of "prostate cancer screening" to mean medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a physician, including, but not limited to: (1) urinary analysis; (2) serum biomarkers; (3) medical imaging, including, but not limited to, magnetic resonance imaging. The bill also extends the prostate cancer screening requirements to commercial individual health insurers, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, the State Health Benefits Program, and the School Employees' Health Benefits Program, which are not required to provide this coverage under current law.

AI Summary

This bill requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group and individual health insurers to provide coverage for an annual prostate cancer screening without any cost-sharing requirements for men between 40 and 75 years of age. The bill expands the definition of "prostate cancer screening" to include not only digital rectal exams and prostate-specific antigen (PSA) tests, but also subsequent follow-up testing such as urinary analysis, serum biomarkers, and medical imaging. The requirements also apply to the State Health Benefits Program and the School Employees' Health Benefits Program.

Committee Categories

Budget and Finance, Business and Industry

Sponsors (4)

Last Action

Referred to Senate Budget and Appropriations Committee (on 06/09/2022)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...